Last edition
News about "ETCAMAH"
US FDA Approves ETCAMAH Plus CDK4/6 Inhibitor for Advanced HR-Positive Breast Cancer
US approves ETCAMAH (camizestrant) plus a CDK4/6 inhibitor for first-line advanced HR-positive breast cancer, reducing progression or death risk by 56 percent.
ETCAMAH | 05/09/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members